Anti-inflammatory drugs against melanoma, a serious cancer of the skin. A study begins in Toulouse
Published the 26.01.2018 at 14h53
Update the 26.01.2018 at 18h42
Still a first world medical to the credit of France. And in an area where hope is important : improving outcomes in melanoma, a skin cancer dreaded because it too often causes metastases. A study has just been launched by a research team of the Oncopole of Toulouse involving
that are expected to be an explosion of cases, especially in women, due to a very close link with the exhibition summer in the sun.
The revolution in immuno-oncology
First step in this fight against melanoma, immuno-oncology. The principle is simple : combine drugs to combat cancer by developing the natural system of defence of the human person, the immune system, which is often modified by the cancer itself. By helping the soldiers of the immunity, that are T lymphocytes, to recognize and destroy the cancerous cell.
Simple principle but one that has taken years to develop weapons very targeted, of which the first examples date back to the early years 2010. With results never seen before in oncology. If the melanoma was the first cancer to benefit from them, have tracked the bladder, the kidney and the lung… If the melanoma has been the first to see releases of victory, it is also the first cancer for which scientists have begun to look for ways of success for the other, the ” non-responders “.
One of the tracks of response is that of inflammation. In addition to hide vis-à-vis T cells, the cancerous cell causes an inflammatory reaction, very violent when she is attacked, which has the effect of reducing the response to the medicine anti cancer.
Hence the temptation to give, in combination, molecules anti-inflammatories, all that we have today very powerful, that patients who have inflammatory arthritis are familiar. Drugs that have, in those other diseases, changed from how amazing the lives of these patients.
Two brilliant French researchers, a Professor of Dermatology, a specialist in breast cancer at the hospital of Toulouse and the international reputation well established, Professor Nicholas Meyer, as the teams Why Doctor often encounter in the great American congress and European, in collaboration with professor Bruno Ségui, researcher in biology at the Oncopole of Toulouse, issued a statement, via the AFP.
They announce the world’s first test in 18 patients of the addition of an anti-TNF alpha, the latest generation of anti-inflammatory drugs that are very powerful… but also generating potential side effects.
See you in two years…
This is why the researchers give rendez-vous in two years, whether the experiment is effective, safe, and, therefore, generalizable to all patients with melanoma.
And probably in the long term to all those who will be processing immuno oncology. A challenge that is significant and highly anticipated by the quality of the reasoning and of those who apply.